Seeking Alpha

NuVasive (NUVA) lowers its Q3 outlook, saying it anticipates revenue to be around $147M, below...

NuVasive (NUVA) lowers its Q3 outlook, saying it anticipates revenue to be around $147M, below earlier expectations for flat sequential revenue growth. The company experienced unusually high account churn related primarily to the growth of surgeon participation in physician-owned distributorships and to increasingly aggressive tactics from its competitors. Additionally, it heard from many surgeon customers of "increased delays and denials from insurance payers", and will provide revised full year guidance on its October 29th earnings conference call. Shares -21% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)